New patent for Eli Lilly drug REYVOW

Reyvow is a drug marketed by Eli Lilly And Co and is included in one NDA. It is offered from one supplier. There are 2 patents securing this drug.

Copyright ©
DrugPatentWatch. Originally released at
New patent for Eli Lilly drug REYVOWAnnual Drug Patent Expirations for REYVOW

The generic active ingredient in REYVOW is lasmiditan succinate. One provider is listed for this substance. Additional details are offered on the lasmiditan succinate profile page.

REYVOW drug rate patterns.

For more details on how DrugPatentWatch can aid with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

This drug has thirty-eight patent member of the family in thirty nations.

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright ©
DrugPatentWatch. Originally released at
New patent for Eli Lilly drug REYVOW

Share this:

Reyvow is a drug marketed by Eli Lilly And Co and is consisted of in one NDA. There are two patents protecting this drug.

Related

LinkedIn
Twitter
Facebook
Email

The generic active ingredient in REYVOW is lasmiditan succinate. Additional information are readily available on the lasmiditan succinate profile page.